WO1998049300A3 - Truncated vegf-related proteins - Google Patents
Truncated vegf-related proteins Download PDFInfo
- Publication number
- WO1998049300A3 WO1998049300A3 PCT/US1998/007801 US9807801W WO9849300A3 WO 1998049300 A3 WO1998049300 A3 WO 1998049300A3 US 9807801 W US9807801 W US 9807801W WO 9849300 A3 WO9849300 A3 WO 9849300A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vrps
- truncated
- related proteins
- useful
- nucleic acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA199900861A EA199900861A1 (en) | 1997-04-25 | 1998-04-20 | TRACKED PROTEINS, RELATED GROWTH ENDOTHELIUM GROWTH FACTOR |
EP98919794A EP0977854A2 (en) | 1997-04-25 | 1998-04-20 | Truncated vegf-related proteins |
JP54706298A JP2001524828A (en) | 1997-04-25 | 1998-04-20 | Truncated VEGF-related protein |
NZ500530A NZ500530A (en) | 1997-04-25 | 1998-04-20 | Truncated VEGF-B, VEGF-C, VEGF-3, PlGF, VRF-2, poxvirus ORF-1 and ORF-2 proteins |
AU72502/98A AU7250298A (en) | 1997-04-25 | 1998-04-20 | Truncated vegf-related proteins |
CA002287538A CA2287538A1 (en) | 1997-04-25 | 1998-04-20 | Truncated vegf-related proteins |
IL13253798A IL132537A0 (en) | 1997-04-25 | 1998-04-20 | Truncated vegf-related proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84298497A | 1997-04-25 | 1997-04-25 | |
US08/842,984 | 1997-04-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998049300A2 WO1998049300A2 (en) | 1998-11-05 |
WO1998049300A3 true WO1998049300A3 (en) | 1999-03-11 |
Family
ID=25288752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/007801 WO1998049300A2 (en) | 1997-04-25 | 1998-04-20 | Truncated vegf-related proteins |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0977854A2 (en) |
JP (1) | JP2001524828A (en) |
KR (1) | KR20010020259A (en) |
CN (2) | CN1260835A (en) |
AU (1) | AU7250298A (en) |
CA (1) | CA2287538A1 (en) |
EA (1) | EA199900861A1 (en) |
IL (1) | IL132537A0 (en) |
NZ (2) | NZ514872A (en) |
WO (1) | WO1998049300A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9228205B2 (en) | 2000-11-15 | 2016-01-05 | Crucell Holland B.V. | Complementing cell lines |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5932540A (en) | 1994-03-08 | 1999-08-03 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
CA2184584C (en) | 1994-03-08 | 2003-04-08 | Jing-Shan Hu | Vascular endothelial growth factor 2 |
US6734285B2 (en) | 1994-03-08 | 2004-05-11 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 proteins and compositions |
US7153827B1 (en) | 1994-03-08 | 2006-12-26 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 and methods of use |
US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
US7109308B1 (en) | 1994-03-08 | 2006-09-19 | Human Genome Sciences, Inc. | Antibodies to human vascular endothelial growth factor 2 |
US7186688B1 (en) | 1994-03-08 | 2007-03-06 | Human Genome Sciences, Inc. | Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2 |
US6040157A (en) * | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
EP1382679A3 (en) | 1995-09-08 | 2004-11-10 | Genentech, Inc. | Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists |
US7125714B2 (en) | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
AU3072099A (en) * | 1998-03-13 | 1999-09-27 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
DE19813774A1 (en) * | 1998-03-27 | 1999-09-30 | Max Planck Gesellschaft | Parapox virus-encoded vascular endothelial cell growth factor (PPV-VEGF) |
CA2331601A1 (en) * | 1998-03-27 | 1999-10-07 | Charles Little | Vegf and vegf-c as infant formula supplements |
WO2000014105A1 (en) | 1998-09-08 | 2000-03-16 | Agouron Pharmaceuticals, Inc. | Modifications of the vegf receptor-2 protein and methods of use |
EP1568375A1 (en) * | 1998-10-26 | 2005-08-31 | Ludwig Institute For Cancer Research | Use of VEGF-C or VEGF-D gene or protein to prevent restenosis |
WO2000024412A2 (en) * | 1998-10-26 | 2000-05-04 | Ludwig Institute For Cancer Research | Use of vegf-c or vegf-d gene or protein to prevent restenosis |
US6958147B1 (en) | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
ES2316194T3 (en) | 1998-10-28 | 2009-04-01 | Cornell Research Foundation, Inc. | METHODS FOR THE REGULATION OF ANGIOGENESIS AND VASCULAR INTEGRITY USING THE BDNF, NT-3 AND NT-4 LIGANDS. |
US6783953B1 (en) | 1998-12-22 | 2004-08-31 | Janssen Pharmaceutica N.V. | Vascular endothelial growth factor-X |
US7223724B1 (en) | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
US7727971B2 (en) | 2000-02-04 | 2010-06-01 | Life Sciences Research Partners Vzw | Use of placental growth factor for treating ischemic muscle disease |
WO2001057181A2 (en) * | 2000-02-04 | 2001-08-09 | Carmeliet, Peter | Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke |
CA2405291A1 (en) * | 2000-04-06 | 2001-10-18 | Wayne P. Franco | Methods of using growth factors for treating heart disease |
EP1157999A1 (en) * | 2000-05-24 | 2001-11-28 | Introgene B.V. | Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof |
EP1313512A4 (en) | 2000-08-04 | 2004-08-25 | Human Genome Sciences Inc | Vascular endothelial growth factor 2 |
WO2002014367A1 (en) | 2000-08-10 | 2002-02-21 | Center For Advanced Science And Technology Incubation,Ltd. | Chimeric human-type vascular endothelial cell growth factor |
EP1191104A1 (en) * | 2000-09-26 | 2002-03-27 | Introgene B.V. | Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
AU2002228841C1 (en) | 2000-12-07 | 2006-11-23 | Sangamo Biosciences, Inc | Regulation of angiogenesis with zinc finger proteins |
US7402312B2 (en) | 2001-04-13 | 2008-07-22 | Human Genome Sciences, Inc. | Antibodies to vascular endothelial growth factor 2 (VEGF-2) |
CA2444632A1 (en) | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US7709450B2 (en) | 2001-06-20 | 2010-05-04 | Ludwig Institute For Cancer Research | Stimulation of vascularization with VEGF-B-186 |
DE60216310T2 (en) | 2001-10-15 | 2007-06-21 | Janssen Pharmaceutica N.V. | SUBSTITUTED 4-PHENYL-4- (1H-IMIDAZOLE-2-YL) -PIPERIDINE DERIVATIVES TO REDUCE ISCHEMIC INJURY |
WO2006055743A2 (en) * | 2004-11-18 | 2006-05-26 | Franco, Wayne | Compbination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs |
WO2010078624A1 (en) * | 2009-01-07 | 2010-07-15 | Vegenics Limited | Materials and methods for the treatment of hypertension |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992006194A1 (en) * | 1990-09-27 | 1992-04-16 | Consiglio Nazionale Delle Ricerche | Nucleotide sequences coding for a human protein with angiogenesis regulative properties |
WO1994011506A1 (en) * | 1992-11-18 | 1994-05-26 | Arch Development Corporation | Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle |
WO1996027007A1 (en) * | 1995-03-02 | 1996-09-06 | Amrad Operations Pty. Ltd. | A novel growth factor and a genetic sequence encoding same |
WO1996026742A1 (en) * | 1995-02-28 | 1996-09-06 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
WO1996026736A1 (en) * | 1995-03-01 | 1996-09-06 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b |
WO1996039421A1 (en) * | 1995-06-06 | 1996-12-12 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 3 |
WO1997005250A2 (en) * | 1995-08-01 | 1997-02-13 | Helsinki University Licensing Ltd. Oy | Receptor ligand vegf-c |
-
1998
- 1998-04-20 EP EP98919794A patent/EP0977854A2/en not_active Withdrawn
- 1998-04-20 CN CN98806232A patent/CN1260835A/en active Pending
- 1998-04-20 EA EA199900861A patent/EA199900861A1/en unknown
- 1998-04-20 JP JP54706298A patent/JP2001524828A/en not_active Ceased
- 1998-04-20 KR KR1019997009857A patent/KR20010020259A/en not_active Application Discontinuation
- 1998-04-20 IL IL13253798A patent/IL132537A0/en unknown
- 1998-04-20 AU AU72502/98A patent/AU7250298A/en not_active Abandoned
- 1998-04-20 NZ NZ514872A patent/NZ514872A/en unknown
- 1998-04-20 CN CNA200510009104XA patent/CN1680442A/en active Pending
- 1998-04-20 WO PCT/US1998/007801 patent/WO1998049300A2/en not_active Application Discontinuation
- 1998-04-20 NZ NZ500530A patent/NZ500530A/en unknown
- 1998-04-20 CA CA002287538A patent/CA2287538A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992006194A1 (en) * | 1990-09-27 | 1992-04-16 | Consiglio Nazionale Delle Ricerche | Nucleotide sequences coding for a human protein with angiogenesis regulative properties |
WO1994011506A1 (en) * | 1992-11-18 | 1994-05-26 | Arch Development Corporation | Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle |
WO1996026742A1 (en) * | 1995-02-28 | 1996-09-06 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
WO1996026736A1 (en) * | 1995-03-01 | 1996-09-06 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b |
WO1996027007A1 (en) * | 1995-03-02 | 1996-09-06 | Amrad Operations Pty. Ltd. | A novel growth factor and a genetic sequence encoding same |
WO1996039421A1 (en) * | 1995-06-06 | 1996-12-12 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 3 |
WO1997005250A2 (en) * | 1995-08-01 | 1997-02-13 | Helsinki University Licensing Ltd. Oy | Receptor ligand vegf-c |
Non-Patent Citations (1)
Title |
---|
PEPPER M.S. ET AL.: "Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 189, no. 2, 15 December 1992 (1992-12-15), pages 824 - 831, XP002078851 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9228205B2 (en) | 2000-11-15 | 2016-01-05 | Crucell Holland B.V. | Complementing cell lines |
Also Published As
Publication number | Publication date |
---|---|
KR20010020259A (en) | 2001-03-15 |
NZ514872A (en) | 2005-01-28 |
CA2287538A1 (en) | 1998-11-05 |
EA199900861A1 (en) | 2000-06-26 |
EP0977854A2 (en) | 2000-02-09 |
CN1680442A (en) | 2005-10-12 |
AU7250298A (en) | 1998-11-24 |
CN1260835A (en) | 2000-07-19 |
JP2001524828A (en) | 2001-12-04 |
IL132537A0 (en) | 2001-03-19 |
WO1998049300A2 (en) | 1998-11-05 |
NZ500530A (en) | 2001-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998049300A3 (en) | Truncated vegf-related proteins | |
WO2004061456A3 (en) | Uses of hmgb, hmgn, hmga proteins | |
WO1999040197A3 (en) | Variants of the angiogenic factor vascular endothelial cell growth factor: vegf | |
WO2002014358A3 (en) | Novel secreted proteins and their uses | |
IL150566A0 (en) | Nucleic acids and polypeptides and nogo-receptor proteins | |
PT1232264E (en) | Human fgf-21 gene and gene expression products | |
WO2001062794A3 (en) | 18607, a human calcium channel | |
IL112873A (en) | Rapamycin-fkbp12 binding proteins, their isolation and their use | |
WO2000024412A3 (en) | Use of vegf-c or vegf-d gene or protein to prevent restenosis | |
WO1995025171A3 (en) | Dna sequences for matrix metalloproteases, their production and use | |
DK1025237T3 (en) | Human checkpoint kinase, hCDS1, preparations and methods | |
WO2002050111A3 (en) | Isolated laminin 10 | |
IL128569A0 (en) | Fibroblast growth factor homologous factor S(FHFs) and methods of use | |
WO1995034669A3 (en) | Retroviral gene therapy vectors and therapeutic methods based thereon | |
WO2001043693A3 (en) | Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef | |
WO2001031008A3 (en) | Human and rat fgf-20 genes and gene expression products | |
WO2002032939A3 (en) | Secreted proteins and their uses | |
DK0781344T3 (en) | Newly known implant and novel vector for the treatment of acquired diseases | |
DK1165102T3 (en) | Matrix protein preparations for grafting in non-mineralized tissue | |
HUP0202974A2 (en) | Metal-containing ribonucleotide polypeptides | |
WO2002026801A3 (en) | Secreted proteins and their uses | |
WO2002048361A3 (en) | Novel secreted proteins and their uses | |
WO2003012121A3 (en) | Collagen xxii, a novel human collagen and uses thereof | |
WO2003016343A3 (en) | USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS | |
WO1998054209A3 (en) | Human mast cell function-associated antigen (mafa) and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 132537 Country of ref document: IL Ref document number: 98806232.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 500530 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2287538 Country of ref document: CA Ref document number: 2287538 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 199900861 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 1998 547062 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998919794 Country of ref document: EP Ref document number: 1019997009857 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 72502/98 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1998919794 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997009857 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019997009857 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998919794 Country of ref document: EP |